View on Pubmed.gov 38787263 | View on doi.org 10.3390/pathoge...
Novel Experimental Mouse Model to Study the Pathogenesis and Therapy of Infection.
- Agricultural Biotechnology Research Center, Academia Sinica, Taipei City 115, Taiwan. Institute of Biotechnology, National Taiwan University, Taipei City 106, Taiwan.
- Agricultural Biotechnology Research Center, Academia Sinica, Taipei City 115, Taiwan.
- Animal Technology Research Center, Agricultural Technology Research Institute, Miaoli County 350, Taiwan.
- Institute of Biotechnology, National Taiwan University, Taipei City 106, Taiwan.
- Department of Life Sciences, National Taiwan Ocean University, Keelung City 202, Taiwan.
- Graduate Institute of Integrated Medicine, China Medical University, Taichung City 404, Taiwan.
- Department of Life Sciences, National Chung-Hsing University, Taichung City 404, Taiwan.
Abstract
(APP) is a major cause of lung infections in pigs. An experimental mouse has the edge over pigs pertaining to the ease of experimental operation, disease study and therapy, abundance of genetic resources, and cost. However, it is a challenge to introduce APP into a mouse lung due to the small respiratory tract of mice and bacterial host tropism. In this study, an effective airborne transmission of APP serovar 1 (APP1) was developed in mice for lung infection. Consequently, APP1 infected BALB/c mice and caused 60% death within three days of infection at the indicated condition. APP1 seemed to enter the lung and, in turn, spread to other organs of the mice over the first 5 days after infection. Accordingly, APP1 damaged the lung as evidenced by its morphological and histological examinations. Furthermore, ampicillin fully protected mice against APP1 as shown by their survival, clinical symptoms, body weight loss, APP1 count, and lung damages. Finally, the virulence of two extra APP strains, APP2 and APP5, in the model was compared based on the survival rate of mice. Collectively, this study successfully established a fast and reliable mouse model of APP which can benefit APP research and therapy. Such a model is a potentially useful model for airway bacterial infections.
References
Sci Rep. 2016 Apr 05;6:24058
PLoS One. 2014 Apr 14;9(4):e94953
PLoS One. 2022 Oct 13;17(10):e0276130
J Med Virol. 2019 Nov;91(11):1918-1929
Cited by 2 citations (total)
Journal Article Research Support, Non-U.S. Gov't
Immunogenicity and vaccine efficacy of Actinobacillus pleuropneumoniae-derived extracellular vesicles as a novel vaccine candidate.
Electronic publication date January 20, 2025
Su Hyun Park [...] Woo Sik Kim et al.
Actinobacillus pleuropneumoniae (APP) is a significant pathogen in the swine industry, leading to substantial economic losses and highlighting the need...
Journal Article Review
experimental model to test new antimicrobials: a methodological approach.
Electronic publication date November 21, 2024
Maria Vidal [...] Pere-Joan Cardona et al.
Given the increasing concern about antimicrobial resistance among the microorganisms that cause infections in our society, there is an urgent...
Conflict of interest statement
MeSH
- •
- •
- •
- •
Specialties
- •
Substances
- •